WO2011027988A2 - Novel polymorphic form of prasugrel-hydrogen sulfate - Google Patents

Novel polymorphic form of prasugrel-hydrogen sulfate Download PDF

Info

Publication number
WO2011027988A2
WO2011027988A2 PCT/KR2010/005632 KR2010005632W WO2011027988A2 WO 2011027988 A2 WO2011027988 A2 WO 2011027988A2 KR 2010005632 W KR2010005632 W KR 2010005632W WO 2011027988 A2 WO2011027988 A2 WO 2011027988A2
Authority
WO
WIPO (PCT)
Prior art keywords
prasugrel
hydrogen sulfate
polymorphic
crystalline form
acid
Prior art date
Application number
PCT/KR2010/005632
Other languages
French (fr)
Other versions
WO2011027988A3 (en
Inventor
Chang Hee Park
Jong Ouk Baek
Kwee Hyun Suh
Tae Hee Ha
Myoung Sil Ko
Gwan Sun Lee
Eun Young Byun
Original Assignee
Hanmi Holdings Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co., Ltd. filed Critical Hanmi Holdings Co., Ltd.
Publication of WO2011027988A2 publication Critical patent/WO2011027988A2/en
Publication of WO2011027988A3 publication Critical patent/WO2011027988A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to novel polymorphic form of prasugrel- hydrogen sulfate having improved physical and pharmaceutical properties, a preparation method thereof, and a pharmaceutical composition comprising the same.
  • Prasugrel (2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7- tetrahydrothieno[3,2-c]pyridine), was first described in European Patent No. 542,411 as an antagonist of purinergic adenosine 5 '-diphosphate receptor P2Y 12 .
  • Prasugrel is a pharmacological antithrombotic agent which inhibits the platelet- aggregation, and accordingly, it has been acknowledged as one of therapeutic agents for preventing or treating ischemic diseases such as acute coronary artery syndrome.
  • An active ingredient of a pharmaceutical composition is required to be stable during the preparation process which involves grinding, mixing, granulating, and compressing steps, as well as good storage stability. Also, such active ingredient is required to be non-hygroscopic, fluidic, and non-electrostatic, which can be released so as to provide its quick systemic uptake by the body of a mammal after its administration.
  • prasugrel does not have all such physical and pharmaceutical properties required of an active ingredient. Therefore, there have been conducted many studies to use various acid-addition salts or crystalline forms of prasugrel as the active ingredient of a pharmaceutical composition.
  • European Patent No. 542,411 has disclosed thieno[3,2- c]pyridine derivatives having platelet-aggregation inhibition activity or a pharmaceutically acceptable salt thereof together with prasugrel.
  • the pharmaceutically acceptable salt include acid-addition salts of inorganic acids, low alkylsulfonic acids, and carboxylic acids.
  • WO 2007/114526 has disclosed a method for preparing highly pure prasugrel and acid-addition salts thereof.
  • the disclosed salts of prasugrel are acid-addition salts derived using an inorganic acid such as sulfonic acid, hydrochloric acid, nitric acid, or phosphoric acid; or an organic acid such as trifluoroacetic acid, maleic acid, methansulfonic acid, or p- toluensulfonic acid.
  • an inorganic acid such as sulfonic acid, hydrochloric acid, nitric acid, or phosphoric acid
  • organic acid such as trifluoroacetic acid, maleic acid, methansulfonic acid, or p- toluensulfonic acid.
  • prasugrel hydrochloride alone has been described in the example.
  • International Patent Publication No. WO 2009/066326 has disclosed a method for preparing prasugrel and acid-addition salts thereof.
  • the disclosed salts of prasugrel are acid-addition salts derived using hydrochloric acid, bromic acid, benzenesulfonic acid, maleic acid, oxalic acid, fumaric acid, succinic acid, p-toluensulfonic acid, and malic acid.
  • the preparation examples describe only prasugrel fumarate, maleate, hydrochloride, benzenesulfonate, and p-toluensulfonate.
  • China Patent Publication No. 1,255,169 has disclosed a method for preparing prasugrel and conventional salts thereof.
  • the disclosed conventional salts of prasugrel are acid-addition salts of methansulfonic acid, fumaric acid, acetic acid, oxalic acid, succinic acid, tartaric acid, 2- hydroxybenzoic acid, acetylsalicylic acid, hydrobromic acid, hydroiodic acid, sulfonic acid, and phosphoric acid.
  • the preparation examples describe only prasugrel methansulfonate, hydrobromoride, hydroiodide, and 2- hydroxybenzoate.
  • the present inventors have endeavored to develop a prasugrel acid- addition salt or a crystalline form thereof having the required properties, and have found that a novel polymorphic prasugrel-hydrogen sulfate (crystalline form (I) and (II)) obtained by treating prasugrel with sulfuric acid exhibits markedly improved physical and pharmaceutical properties.
  • the polymorphic prasugrel-hydrogen sulfate is of a crystalline form (I) whose X-ray diffraction (hereinafter, referred to XRD) spectrum obtained using Cu- ⁇ radiation shows major peaks at diffraction angles (2 ⁇ ) of 8.3 ⁇ 0.2 ° , 12.0 ⁇ 0.2 ⁇ 12.4 ⁇ 0.2 ⁇ 19.1 ⁇ 0.2 ° , 19.5 ⁇ 0.2 ° , 22.6 ⁇ 0.2 ° , 23.2 ⁇ 0.2 ° , and 23.8 ⁇ 0.2°; and a crystalline form (II) whose X-ray diffraction spectrum obtained using Cu- Ka radiation shows major peaks at diffraction angles (2 ⁇ ) of 8.6 ⁇ 0.2 ° , 12.8 ⁇ 0.2°, 13.7 ⁇ 0.2 ⁇ 17.5 ⁇ 0.2 ⁇ 19.3 ⁇ 0.2 ° , 19.7 ⁇ 0.2 ° , 22.6 ⁇ 0.2 ° , 23.7 ⁇ 0.2 ° , and 24.2 ⁇ 0.2 ° .
  • XRD X-ray diffraction
  • a method for preparing said compound which comprises a step of treating prasugrel with sulfuric acid in an inert organic solvent to induce crystallization of said compound, wherein the inert organic solvent for preparing the crystalline form (I) of the inventive prasugrel-hydrogen sulfate is Ci-C 6 alcohol; and a mixture of C r C6 alcohol and at least one solvent selected from the group consisting of ester, ether and nitriles, and the inert organic solvent for preparing the crystalline form (II) of the inventive prasugrel-hydrogen sulfate is ketone; or a mixture of ketone and at least one solvent selected from the group consisting of ester, ether and nitriles.
  • a pharmaceutical composition for preventing or treating an ischemic disease which comprises said compound as an active ingredient, together with a pharmaceutically acceptable carrier, diluent, or excipient.
  • Fig. 1 an XRD spectrum of the crystalline form (I) of the inventive prasugrel-hydrogen sulfate obtained in Example 2;
  • Fig. 2 a differential scanning calorimeter (DSC) scan of the crystalline form (I) the inventive prasugrel-hydrogen sulfate obtained in Example 2;
  • Fig. 3 an XRD spectrum of the crystalline form (II) of the inventive prasugrel-hydrogen sulfate obtained in Example 6;
  • Fig. 4 a DSC scan of the crystalline form (II) of the inventive prasugrel- hydrogen sulfate obtained in Example 6; and Fig. 5: a dynamic vapor sorption (DVS) scan of the crystalline form (I) of the inventive prasugrel-hydrogen sulfate obtained in Example 6.
  • DSC dynamic vapor sorption
  • polymorph refers to different crystal packing arrangements of a molecular species.
  • inventive polymorphic prasugrel- hydrogen sulfate comprises crystalline forms (I) and (II) thereof.
  • inventive polymorphic prasugrel-hydrogen sulfate (crystalline forms
  • (I) and (II)) is a novel acid addition salt composed of one molecule of prasugrel and one molecule of sulfuric acid in a molar equivalent ratio of 1:1, which can be confirmed by ion chromatography (IC) analysis.
  • IC ion chromatography
  • Crystalline form (I) of prasugrel-hydrogen sulfate shows major peaks at diffraction angles (20) of 8.3 ⁇ 0.2 ⁇ 12.0 ⁇ 0.2 ⁇ 12.4 ⁇ 0.2°, 19.1 ⁇ 0.2°, 19.5 ⁇ 0.2°, 22.6 ⁇ 0.2 ⁇ 23.2 ⁇ 0.2°, and 23.8 ⁇ 0.2 ° (see, Fig. 1).
  • the melting point of the crystalline form (I) of the inventive prasugrel- hydrogen sulfate is in the range of 104 °C to 107 ° C determined by thermogravity capillary analysis.
  • the differential scanning calorimetry (hereinafter, referred to DSC) scan of the crystalline form (I) of the inventive prasugrel-hydrogen sulfate shows endothermic peak with an onset point at 105.18 ⁇ 2 °C and a minimum point at 115.87 ⁇ 2 ° C which corresponds to said melting point (see, Fig. 2).
  • the XRD spectrum obtained using Cu- ⁇ radiation of the crystalline form (II) of the inventive prasugrel-hydrogen sulfate shows major peaks at diffraction angles (2 ⁇ ) of 8.6 ⁇ 0.2 ° , 12.8 ⁇ 0.2 ⁇ 13.7 ⁇ 0.2 ⁇ 17.5 ⁇ 0.2 ⁇ 19.3 ⁇ 0.2 ⁇ 19.7 ⁇ 0.2 ⁇ 22.6 ⁇ 0.2 ° , 23.7 ⁇ 0.2°, and 24.2 ⁇ 0.2° (see, Fig. 3).
  • the melting point of the crystalline form (II) of the inventive prasugrel- hydrogen sulfate is in the range of 153 ° C to 160 ° C , preferably 156 ° C to 160 ° C determined by thermogravity capillary analysis, which is higher than that of the crystalline form (I).
  • the DSC scan of the crystalline form (II) of the inventive prasugrel- hydrogen sulfate shows endothermic peak with an onset point at 162.46 ⁇ 2 ° C and a minimum point at 167.91 ⁇ 2 °C which corresponds to said melting point (see, Fig. 4).
  • the crystalline form (II) of the inventive prasugrel-hydrogen sulfate exhibits non-hygroscopic in the room humidity level. Specifically the difference of water content of the crystalline form (II) of the inventive prasugrel-hydrogen sulfate measured by dynamic vapor sorption (hereinafter, referred to DVS) of less than 1.0 % was determined at a relative humidity of 80 % or less, and the difference of water content measured by DVS of less than 2.1 % was determined at a relative humidity of 80 % or less.
  • DVS dynamic vapor sorption
  • the crystalline form of the pharmaceutical ingredients can be determined by at least one selected from the group consisting of the melting point, the spectrum of XRD, DSC, solid state nuclear magnetic resonance spectroscopy, infrared (IR) spectroscopy and raman spectroscopy, and hydrates.
  • the diffraction angles (20) and distance between crystal facets (d value) in the XRD spectrum are a major factor to determine the crystalline form of the pharmaceutical ingredients.
  • the homogeneity of pharmaceutical ingredients is one of the permission requirements for the drug. It is important that the homogeneity of pharmaceutical ingredients should satisfy the specification and such homogeneity is the same to each of batch for preparing the drug. Drug administration requires to the manufacturer to meet these requirements.
  • the inventive polymorphic prasugrel- hydrogen sulfate characterized by XRD spectrum, DSC scan and melting point will be identified as a uniform state within the margin of error, regardless of preparation arrangement, drying time, storage period, storage method and measurement method.
  • the inventive polymorphic prasugrel-hydrogen sulfate of formula (I) may be prepared by a method which comprises the step of treating prasugrel with sulfuric acid in an inert organic solvent to induce crystallization of the prasugrel- hydrogen sulfate.
  • the inert organic solvent used in the inventive reaction may be an organic solvent which not reacts with prasugrel or sulfuric acid and does not cause a reverse effect on a crystallization of the prasugrel-hydrogen sulfate.
  • Examples of the inert organic solvent for preparing the crystalline form (I) of the inventive prasugrel-hydrogen sulfate include, but are not limited to, C C 6 alcohol (e.g., methanol, ethanol, isopropanol, or 2-butanol); and a mixture of C r C 6 alcohol and at least one solvent selected from the group consisting of ester (e.g., methyl acetate, ethyl acetate, n-propylacetate or isopropylacetate), ether (e.g., tetrahydrofuran, isopropyl ether, or ethyl ether) and nitriles (e.g., acetonitrile).
  • C C 6 alcohol e.g., methanol, ethanol, isopropanol, or 2-butanol
  • the solvent selected from the group consisting of isopropanol, 2-butanol, a mixture of isopropanol and ethyl acetate, and a mixture of 2-butanol and ethyl acetate for preparing the crystalline form (I) of the inventive prasugrel-hydrogen sulfate.
  • Examples of the inert organic solvent for preparing the crystalline form (II) of the inventive prasugrel-hydrogen sulfate include, but are not limited to, ketone (e.g., acetone, methyl ethyl ketone, methyl isobutyl ketone or diethyl ketone); and a mixture of ketone and at least one solvent selected from the group consisting of ester (e.g., methyl acetate, ethyl acetate, n-propylacetate or isopropylacetate), ether (e.g., tetrahydrofiiran, isopropyl ether, or ethyl ether) and nitriles (e.g., acetonitrile).
  • ester e.g., methyl acetate, ethyl acetate, n-propylacetate or isopropylacetate
  • ether e.g., tetrahydrof
  • the solvent selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, diethyl ketone, and a mixture of acetone and ethyl acetate for preparing the crystalline form (II) of the inventive prasugrel-hydrogen sulfate.
  • the amount of the inert organic solvent used in the reaction is ranging from 1 ml to 30 ml, preferably 5 ml to 15 ml based on one gram of the prasugrel.
  • the sulfuric acid is used in an amount corresponding to 0.7 to 1.5 mole equivalents, preferably 0.9 to 1.2 mole equivalents based on 1 mole equivalent of prasugrel.
  • the prasugrel used in the inventive method may be prepared by any one of the conventional methods (European Patent No. 542,411 or International Patent Publication No. WO 2002/04461) or others, and it may be a purified or crude one.
  • the prasugrel may be treated with sulfuric acid at a temperature of 0 ° C to a boiling point of the inert organic solvent used in the reaction, preferably 10 °C to 50 ° C . Further, the precipitation of crystalline after the reaction is carried out at -20 ° C to 50 ° C , preferably, 0 ° C to room temperature. Also, seed crystalline may be used for inducing the precipitation of the crystalline of the prasugrel-hydrogen sulfate.
  • the inventive method further comprises the step of dissolving the obtained polymorphic prasugrel-hydrogen sulfate in an inert organic solvent, followed by re-crystallization of the resulting solution.
  • the inert organic solvent is the same as defined above.
  • the polymorphic prasugrel-hydrogen sulfate prepared in the present invention has a high chemical purity of 98.5 % or higher which meets the purity requirement of the pharmaceutical ingredient.
  • the prasugrel is an antithrombotic agent which strongly inhibits purinergic adenosine 5' -diphosphate receptor P2Y 12 involved in the platelet- aggregation, and is useful for preventing and treating an ischemic disease such as acute coronary artery syndrome.
  • an ischemic disease such as acute coronary artery syndrome.
  • the inventive polymorphic prasugrel- hydrogen sulfate is introduced to gastrointestinal tract or in vivo, the prasugrel is released from the polymorphic prasugrel-hydrogen sulfate, accordingly, the inventive polymorphic prasugrel-hydrogen sulfate can be useful in preventing and treating the ischemic disease caused by the platelet-aggregation.
  • a pharmaceutical composition for preventing or treating an ischemic disease which comprises the polymorphic prasugrel-hydrogen sulfate as an active ingredient, together with a pharmaceutically acceptable carrier, diluent, or excipient.
  • the pharmaceutical composition comprising the polymorphic prasugrel- hydrogen sulfate in a specific amount may be administered to a patient in need thereof via various routes including oral or parentral administration, preferably an oral administration.
  • the composition for oral administration may be in the form of capsules, tablets, dispersions, suspensions and the like.
  • the capsule or tablet may include enteric coated capsules or tablets, or enteric coated pellet-containing capsules or tablets.
  • the pharmaceutical composition of the present invention may be prepared by admixing the polymorphic prasugrel-hydrogen sulfate together with a pharmaceutically acceptable carrier, diluent, or excipient.
  • suitable carrier are saline solution, polyethyleneglycol, ethanol, vegetable oil, and isopropyl myristearate
  • suitable diluent are lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine
  • suitable excipient are starch, sugar, lactose, dextrin, mannitol, sorbitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, Arabia gum, amylopectin, hard anhydrous silicic acid, and synthetic aluminum silicate.
  • the pharmaceutical composition may further include pharmaceutically acceptable additives including fillers and bulking agents such as calcium phosphate or silicic acid derivatives; binding agents such as starch, sugar, mannitol, trehalose, dextrin, amylopectin, sucrose, glutin, Arabia gum, cellulose derivatives (e.g., methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose), gelatin, alginate, or polyvinylpyrrolidone; lubricants such as talc, calcium or magnesium stearate, hydrogenated castor oil, talcum powder, or solid-phase polyethylene glycol; disintergents such as povidone, croscarmellose sodium, or crospovidone; and surfactants such as polysorbate, cetyl alcohol, or glycerol monostearate.
  • pharmaceutically acceptable additives including fillers and bulking agents such as calcium phosphate or silicic
  • compositions comprising the polymorphic prasugrel-hydrogen sulfate in a specific amount as an active ingredient together with optional additives such as carriers, diluents, or excipients may be prepared according to conventional methods ⁇ see, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 19 th Edition, 1995).
  • the pharmaceutical composition of the present invention may comprise the polymorphic prasugrel-hydrogen sulfate in an amount ranging from 0.1 to 95% by weight, preferably from 1 to 70% by weight based on the total weight thereof.
  • a proposed daily dose of the polymorphic prasugrel-hydrogen sulfate as an active ingredient for administration to a mammal including human is about from 0.5 to 250 mg/kg body weight, preferably about from 1 to 150 mg/kg body weight, which may be administered in a single dose or in divided doses.
  • UV absorption spectrometer (240 nm);
  • the melting point of the inventive polymorphic prasugrel-hydrogen sulfate was determined using a capillary digital melting point recorder (Barnstead Electrothermal, Great Britain).
  • the water content of the inventive polymorphic prasugrel-hydrogen sulfate was measured using 795 KFT water meter (Metrohm, Switzerland), and the infrared absorption spectrum (IR) was obtained using MB- 100 infrared spectrometer (Bomen, Canada).
  • 1H nuclear magnetic resonance (1H-NMR) spectrum was measured using Avance DPX 300 (Bruker, Germany).
  • DSC Differential scanning calorimeter
  • STA S-1000 (Scinco, Korea) with a temperature programming rate of 10 ° C per a minute.
  • the water content was determined by performing dynamic vapor sorption (DVS) twice, are, moisture sorption and the other, adsorption under the conditions of 25 ° C and relative humidity of 0 to 90 %, using DVS Advantage 1 dynamic vapor sorption system (Surface Measurement System, Great Britain).
  • Example 1 Preparation of the crystalline form (I) of prasugrel-hydrogen sulfate for seeding
  • IR (KBr, cm -1 ): 3403, 1764, 1712, 1614, 1588, 1495, 1452, 1377, 1 193, 1123, 1080, 1045, 883, 769, 649, 591.
  • XRD spectrum (CuKa radiation) : 2 theta (20) major peaks having relative peak intensity of at least 25.0 % (I/I 0 ; I: the peak intensity; and I 0 : the peak intensity of the maximum peak) and the distances between crystal facets (d) are shown in Table 1.
  • DSC (10 ° C/min) A DSC scan showed endothermic peak with an onset point at 105.18 ° C and a minimum point at 115.87 ° C which corresponds to the melting point of said compound as shown in Fig. 2.
  • Example 2 Preparation of the crystalline form (I) of prasugrel-hydrogen sulfate
  • Example 6 Preparation of the crystalline form (II) of prasugrel-hydrogen sulfate
  • IR (KBr, cm “1 ): 3405, 1758, 1710, 1588, 1495, 1452, 1374, 1 191, 1 123, 1080, 884, 768, 647, 591, 450.
  • XRD spectrum (CuKa radiation) : 2 theta (2 ⁇ ) major peaks having relative peak intensity of at least 25.0 % (I/I 0 ; I: the peak intensity; and 1Q: the peak intensity of the maximum peak), and the distances between crystal facets (d) are shown in Table 2. Said major peaks are shown in Fig. 3.
  • DSC (10 °C/min) A DSC scan showed endothermic peak with an onset point at 162.46 °C and a minimum point at 167.91 ° C which corresponds to the melting point of said compound as shown in Fig. 4.
  • Example 3 The crystalline form (I) of prasugrel-hydrogen sulfate obtained in Example 3 (10 g, 21.2 mmol) was added to metylethylketone (3 ml) and heated at 60 °C to dissolve. The resulting reaction solution was stirred at room temperature for 24 hrs. The solid formed was filtered, washed with isopropyl ether (5 ml), and dried at 40 °C , to obtain the title compound as a white colored crystal (0.8 g, 80 %).
  • the crystalline form (I) of prasugrel-hydrogen sulfate obtained in Example 3 (1.0 g, 2.12 mmol) was added to a mixture of acetone (3 ml) and ethyl acetate (3 ml) and heated at 50 ° C to dissolve. The resulting reaction solution was stirred at room temperature for 12 hrs. The solid formed was filtered, washed with isopropyl ether (5 ml), and dried at 40 "C , to obtain the title compound as a white colored crystal (0.7 g, 70 %).
  • Example 10 Preparation of the crystalline form (II) of prasugrel-hydrogen sulfate To a suspension of prasugrel (2.0 g, 5.35 mmol) in methyl ethyl ketone (5 ml), sulfuric acid (0.52 g, 5.30 mmol) was added slowly to convert the suspension into a homogenous phase. The crystalline form (II) of prasugrel-hydrogen sulfate obtained in Example 6 was added thereto and stirred at room temperature for 6 hrs. The solid formed was filtered, washed with isopropyl ether (5 ml), and dried at 40 ° C , to obtain the title compound as a white colored crystal (2.1 g, 84 %).
  • Example 5 and 6 (crystallines form (I) and (II)) in pH 1.2(first solution), pH 6.8 (second solution) and distilled water was measured.
  • prasugrel hydrochloride prepared according to the preparation method described in WO 2002/04461 was used. The results were showed in Table 3.
  • the prasugrel-hydrogen sulfate (crystalline forms (I) and (II)) has an improved solubility compared to prasugrel hydrochloride.
  • the prasugrel-hydrogen sulfate (crystalline forms (I) and (II)) of the present invention is characterized by the melting point, diffraction angle peaks and the distances between crystal facets in XRD spectrum analysis, and the temperature in endothermic peaks exhibited by DSC scan.
  • the non-hygroscopicity is an important characteristic required for formulating a pharmaceutical composition and preserving a drug.
  • the crystalline form (I) of prasugrel-hydrogen sulfate has a hygroscopicity under the room humidity level, while the crystalline form (II) of prasugrel-hydrogen sulfate has non-hygroscopicity in the same conditions. Accordingly, the crystalline form (II) of prasugrel-hydrogen sulfate according to the present invention meets such requirement. Further, the crystalline form (II) meets physical and chemical requirements required for a pharmaceutical ingredient such as an antistatic feature and excellent particle flowability and water-solubility.

Abstract

Disclosed are: a novel polymorphic form of prasugrel-hydrogen sulfate having improved physical and pharmaceutical properties, a preparation method thereof, and a pharmaceutical composition for preventing or treating an ischemic disease comprising the same.

Description

NOVEL POLYMORPHIC FORM OF
PRASUGREL-HYDROGEN SULFATE
FIELD OF THE INVENTION
The present invention relates to novel polymorphic form of prasugrel- hydrogen sulfate having improved physical and pharmaceutical properties, a preparation method thereof, and a pharmaceutical composition comprising the same.
BACKGROUND OF THE INVENTION
Prasugrel, (2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7- tetrahydrothieno[3,2-c]pyridine), was first described in European Patent No. 542,411 as an antagonist of purinergic adenosine 5 '-diphosphate receptor P2Y12. Prasugrel is a pharmacological antithrombotic agent which inhibits the platelet- aggregation, and accordingly, it has been acknowledged as one of therapeutic agents for preventing or treating ischemic diseases such as acute coronary artery syndrome.
An active ingredient of a pharmaceutical composition is required to be stable during the preparation process which involves grinding, mixing, granulating, and compressing steps, as well as good storage stability. Also, such active ingredient is required to be non-hygroscopic, fluidic, and non-electrostatic, which can be released so as to provide its quick systemic uptake by the body of a mammal after its administration.
However, prasugrel does not have all such physical and pharmaceutical properties required of an active ingredient. Therefore, there have been conducted many studies to use various acid-addition salts or crystalline forms of prasugrel as the active ingredient of a pharmaceutical composition.
For example, European Patent No. 542,411 has disclosed thieno[3,2- c]pyridine derivatives having platelet-aggregation inhibition activity or a pharmaceutically acceptable salt thereof together with prasugrel. Examples of the pharmaceutically acceptable salt include acid-addition salts of inorganic acids, low alkylsulfonic acids, and carboxylic acids. However, it described no examples of prasugrel acid-addition salts.
International Patent Publication No. WO 2002/04461, on the other hand, has disclosed various acid-addition salts of prasugrel, each prepared by adding an inorganic acid such as sulfonic acid, hydrochloric acid, nitric acid, or phosphoric acid; or an organic acid such as trifluoroacetic acid, maleic acid, methansulfonic acid, or p-toluensulfonic acid. However, the preparation examples have disclosed only prasugrel hydrochloride and maleate salts.
International Patent Publication No. WO 2007/114526 has disclosed a method for preparing highly pure prasugrel and acid-addition salts thereof. The disclosed salts of prasugrel are acid-addition salts derived using an inorganic acid such as sulfonic acid, hydrochloric acid, nitric acid, or phosphoric acid; or an organic acid such as trifluoroacetic acid, maleic acid, methansulfonic acid, or p- toluensulfonic acid. However, the preparation of prasugrel hydrochloride alone has been described in the example.
Also, International Patent Publication No. WO 2009/066326 has disclosed a method for preparing prasugrel and acid-addition salts thereof. The disclosed salts of prasugrel are acid-addition salts derived using hydrochloric acid, bromic acid, benzenesulfonic acid, maleic acid, oxalic acid, fumaric acid, succinic acid, p-toluensulfonic acid, and malic acid. However, the preparation examples describe only prasugrel fumarate, maleate, hydrochloride, benzenesulfonate, and p-toluensulfonate.
Further, China Patent Publication No. 1,255,169 has disclosed a method for preparing prasugrel and conventional salts thereof. The disclosed conventional salts of prasugrel are acid-addition salts of methansulfonic acid, fumaric acid, acetic acid, oxalic acid, succinic acid, tartaric acid, 2- hydroxybenzoic acid, acetylsalicylic acid, hydrobromic acid, hydroiodic acid, sulfonic acid, and phosphoric acid. However, the preparation examples describe only prasugrel methansulfonate, hydrobromoride, hydroiodide, and 2- hydroxybenzoate. The above-mentioned acid-addition salts of prasugrel are not easy to prepare, or the acid-addition salts of prasugrel prepared are often non-crystalline, and thus, there is a need for developing a prasugrel acid-addition salt having improved physical and pharmaceutical properties.
The present inventors have endeavored to develop a prasugrel acid- addition salt or a crystalline form thereof having the required properties, and have found that a novel polymorphic prasugrel-hydrogen sulfate (crystalline form (I) and (II)) obtained by treating prasugrel with sulfuric acid exhibits markedly improved physical and pharmaceutical properties.
SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide a novel polymorphic prasugrel-hydrogen sulfate having improved physical and pharmaceutical properties.
It is another object of the present invention to provide a method for preparing said compound.
It is a further object of the present invention to provide a pharmaceutical composition for preventing or treating an ischemic disease comprising said compound as an active ingredient.
In accordance with one aspect of the present invention, there is provided polymorphic
Figure imgf000004_0001
The polymorphic prasugrel-hydrogen sulfate is of a crystalline form (I) whose X-ray diffraction (hereinafter, referred to XRD) spectrum obtained using Cu-Κα radiation shows major peaks at diffraction angles (2Θ) of 8.3±0.2°, 12.0±0.2\ 12.4±0.2\ 19.1±0.2°, 19.5±0.2°, 22.6±0.2°, 23.2±0.2°, and 23.8±0.2°; and a crystalline form (II) whose X-ray diffraction spectrum obtained using Cu- Ka radiation shows major peaks at diffraction angles (2Θ) of 8.6±0.2°, 12.8±0.2°, 13.7±0.2\ 17.5±0.2\ 19.3±0.2°, 19.7±0.2°, 22.6±0.2°, 23.7±0.2°, and 24.2±0.2°.
In accordance with another aspect of the present invention, there is provided a method for preparing said compound which comprises a step of treating prasugrel with sulfuric acid in an inert organic solvent to induce crystallization of said compound, wherein the inert organic solvent for preparing the crystalline form (I) of the inventive prasugrel-hydrogen sulfate is Ci-C6 alcohol; and a mixture of CrC6 alcohol and at least one solvent selected from the group consisting of ester, ether and nitriles, and the inert organic solvent for preparing the crystalline form (II) of the inventive prasugrel-hydrogen sulfate is ketone; or a mixture of ketone and at least one solvent selected from the group consisting of ester, ether and nitriles.
In accordance with a further aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating an ischemic disease, which comprises said compound as an active ingredient, together with a pharmaceutically acceptable carrier, diluent, or excipient. BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings which respectively show:
Fig. 1 : an XRD spectrum of the crystalline form (I) of the inventive prasugrel-hydrogen sulfate obtained in Example 2;
Fig. 2: a differential scanning calorimeter (DSC) scan of the crystalline form (I) the inventive prasugrel-hydrogen sulfate obtained in Example 2;
Fig. 3 : an XRD spectrum of the crystalline form (II) of the inventive prasugrel-hydrogen sulfate obtained in Example 6;
Fig. 4: a DSC scan of the crystalline form (II) of the inventive prasugrel- hydrogen sulfate obtained in Example 6; and Fig. 5: a dynamic vapor sorption (DVS) scan of the crystalline form (I) of the inventive prasugrel-hydrogen sulfate obtained in Example 6.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "polymorph" refers to different crystal packing arrangements of a molecular species. The inventive polymorphic prasugrel- hydrogen sulfate comprises crystalline forms (I) and (II) thereof. The inventive polymorphic prasugrel-hydrogen sulfate (crystalline forms
(I) and (II)) is a novel acid addition salt composed of one molecule of prasugrel and one molecule of sulfuric acid in a molar equivalent ratio of 1:1, which can be confirmed by ion chromatography (IC) analysis. The polymorphic prasugrel- hydrogen sulfate has not yet been reported previously.
The inventive polymorphic prasugrel-hydrogen sulfate is described in detail as follows.
(1) Crystalline form (I) of prasugrel-hydrogen sulfate In accordance with one aspect of the present invention, the XRD spectrum obtained using Cu- α radiation of the crystalline form (I) of the inventive prasugrel-hydrogen sulfate shows major peaks at diffraction angles (20) of 8.3±0.2\ 12.0±0.2\ 12.4±0.2°, 19.1±0.2°, 19.5±0.2°, 22.6±0.2\ 23.2±0.2°, and 23.8±0.2° (see, Fig. 1).
The melting point of the crystalline form (I) of the inventive prasugrel- hydrogen sulfate is in the range of 104 °C to 107 °C determined by thermogravity capillary analysis.
The differential scanning calorimetry (hereinafter, referred to DSC) scan of the crystalline form (I) of the inventive prasugrel-hydrogen sulfate shows endothermic peak with an onset point at 105.18±2 °C and a minimum point at 115.87±2 °C which corresponds to said melting point (see, Fig. 2).
The difference of water content of the crystalline form (I) of the inventive prasugrel-hydrogen sulfate was determined at a relative humidity ranging from 1 to 90%, which represents the fact that the inventive compound exhibits a hygroscopicity. (2) Crystalline form (II) of prasugrel-hydrogen sulfate
In accordance with one aspect of the present invention, the XRD spectrum obtained using Cu-Κα radiation of the crystalline form (II) of the inventive prasugrel-hydrogen sulfate shows major peaks at diffraction angles (2Θ) of 8.6±0.2°, 12.8±0.2\ 13.7±0.2\ 17.5±0.2\ 19.3±0.2\ 19.7±0.2\ 22.6±0.2°, 23.7±0.2°, and 24.2±0.2° (see, Fig. 3).
The melting point of the crystalline form (II) of the inventive prasugrel- hydrogen sulfate is in the range of 153 °C to 160 °C , preferably 156 °C to 160 °C determined by thermogravity capillary analysis, which is higher than that of the crystalline form (I).
The DSC scan of the crystalline form (II) of the inventive prasugrel- hydrogen sulfate shows endothermic peak with an onset point at 162.46±2 °C and a minimum point at 167.91±2 °C which corresponds to said melting point (see, Fig. 4).
The crystalline form (II) of the inventive prasugrel-hydrogen sulfate exhibits non-hygroscopic in the room humidity level. Specifically the difference of water content of the crystalline form (II) of the inventive prasugrel-hydrogen sulfate measured by dynamic vapor sorption (hereinafter, referred to DVS) of less than 1.0 % was determined at a relative humidity of 80 % or less, and the difference of water content measured by DVS of less than 2.1 % was determined at a relative humidity of 80 % or less.
Generally, the crystalline form of the pharmaceutical ingredients can be determined by at least one selected from the group consisting of the melting point, the spectrum of XRD, DSC, solid state nuclear magnetic resonance spectroscopy, infrared (IR) spectroscopy and raman spectroscopy, and hydrates. Preferably, the diffraction angles (20) and distance between crystal facets (d value) in the XRD spectrum are a major factor to determine the crystalline form of the pharmaceutical ingredients.
Further, according to the guideline and regulation of the preparation method of a pharmaceutical composition promulgated by drug administration, the homogeneity of pharmaceutical ingredients is one of the permission requirements for the drug. It is important that the homogeneity of pharmaceutical ingredients should satisfy the specification and such homogeneity is the same to each of batch for preparing the drug. Drug administration requires to the manufacturer to meet these requirements.
Therefore, in the present invention, the inventive polymorphic prasugrel- hydrogen sulfate characterized by XRD spectrum, DSC scan and melting point will be identified as a uniform state within the margin of error, regardless of preparation arrangement, drying time, storage period, storage method and measurement method.
The inventive polymorphic prasugrel-hydrogen sulfate of formula (I) may be prepared by a method which comprises the step of treating prasugrel with sulfuric acid in an inert organic solvent to induce crystallization of the prasugrel- hydrogen sulfate.
The inert organic solvent used in the inventive reaction may be an organic solvent which not reacts with prasugrel or sulfuric acid and does not cause a reverse effect on a crystallization of the prasugrel-hydrogen sulfate.
Examples of the inert organic solvent for preparing the crystalline form (I) of the inventive prasugrel-hydrogen sulfate include, but are not limited to, C C6 alcohol (e.g., methanol, ethanol, isopropanol, or 2-butanol); and a mixture of Cr C6 alcohol and at least one solvent selected from the group consisting of ester (e.g., methyl acetate, ethyl acetate, n-propylacetate or isopropylacetate), ether (e.g., tetrahydrofuran, isopropyl ether, or ethyl ether) and nitriles (e.g., acetonitrile). It is preferable to use the solvent selected from the group consisting of isopropanol, 2-butanol, a mixture of isopropanol and ethyl acetate, and a mixture of 2-butanol and ethyl acetate for preparing the crystalline form (I) of the inventive prasugrel-hydrogen sulfate. Examples of the inert organic solvent for preparing the crystalline form (II) of the inventive prasugrel-hydrogen sulfate include, but are not limited to, ketone (e.g., acetone, methyl ethyl ketone, methyl isobutyl ketone or diethyl ketone); and a mixture of ketone and at least one solvent selected from the group consisting of ester (e.g., methyl acetate, ethyl acetate, n-propylacetate or isopropylacetate), ether (e.g., tetrahydrofiiran, isopropyl ether, or ethyl ether) and nitriles (e.g., acetonitrile). It is preferable to use the solvent selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, diethyl ketone, and a mixture of acetone and ethyl acetate for preparing the crystalline form (II) of the inventive prasugrel-hydrogen sulfate.
The amount of the inert organic solvent used in the reaction is ranging from 1 ml to 30 ml, preferably 5 ml to 15 ml based on one gram of the prasugrel.
The sulfuric acid is used in an amount corresponding to 0.7 to 1.5 mole equivalents, preferably 0.9 to 1.2 mole equivalents based on 1 mole equivalent of prasugrel.
The prasugrel used in the inventive method may be prepared by any one of the conventional methods (European Patent No. 542,411 or International Patent Publication No. WO 2002/04461) or others, and it may be a purified or crude one.
In the present invention, the prasugrel may be treated with sulfuric acid at a temperature of 0 °C to a boiling point of the inert organic solvent used in the reaction, preferably 10 °C to 50 °C . Further, the precipitation of crystalline after the reaction is carried out at -20 °C to 50 °C , preferably, 0 °C to room temperature. Also, seed crystalline may be used for inducing the precipitation of the crystalline of the prasugrel-hydrogen sulfate.
The inventive method further comprises the step of dissolving the obtained polymorphic prasugrel-hydrogen sulfate in an inert organic solvent, followed by re-crystallization of the resulting solution. The inert organic solvent is the same as defined above.
The polymorphic prasugrel-hydrogen sulfate prepared in the present invention has a high chemical purity of 98.5 % or higher which meets the purity requirement of the pharmaceutical ingredient.
The prasugrel is an antithrombotic agent which strongly inhibits purinergic adenosine 5' -diphosphate receptor P2Y12 involved in the platelet- aggregation, and is useful for preventing and treating an ischemic disease such as acute coronary artery syndrome. When the inventive polymorphic prasugrel- hydrogen sulfate is introduced to gastrointestinal tract or in vivo, the prasugrel is released from the polymorphic prasugrel-hydrogen sulfate, accordingly, the inventive polymorphic prasugrel-hydrogen sulfate can be useful in preventing and treating the ischemic disease caused by the platelet-aggregation.
In accordance with still further aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating an ischemic disease, which comprises the polymorphic prasugrel-hydrogen sulfate as an active ingredient, together with a pharmaceutically acceptable carrier, diluent, or excipient.
The pharmaceutical composition comprising the polymorphic prasugrel- hydrogen sulfate in a specific amount may be administered to a patient in need thereof via various routes including oral or parentral administration, preferably an oral administration. The composition for oral administration may be in the form of capsules, tablets, dispersions, suspensions and the like. The capsule or tablet may include enteric coated capsules or tablets, or enteric coated pellet-containing capsules or tablets.
The pharmaceutical composition of the present invention may be prepared by admixing the polymorphic prasugrel-hydrogen sulfate together with a pharmaceutically acceptable carrier, diluent, or excipient. The representative examples of suitable carrier are saline solution, polyethyleneglycol, ethanol, vegetable oil, and isopropyl myristearate; the representative examples of suitable diluent are lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine; and the representative examples of suitable excipient are starch, sugar, lactose, dextrin, mannitol, sorbitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, Arabia gum, amylopectin, hard anhydrous silicic acid, and synthetic aluminum silicate.
In the present invention, the pharmaceutical composition may further include pharmaceutically acceptable additives including fillers and bulking agents such as calcium phosphate or silicic acid derivatives; binding agents such as starch, sugar, mannitol, trehalose, dextrin, amylopectin, sucrose, glutin, Arabia gum, cellulose derivatives (e.g., methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose), gelatin, alginate, or polyvinylpyrrolidone; lubricants such as talc, calcium or magnesium stearate, hydrogenated castor oil, talcum powder, or solid-phase polyethylene glycol; disintergents such as povidone, croscarmellose sodium, or crospovidone; and surfactants such as polysorbate, cetyl alcohol, or glycerol monostearate.
Further, the pharmaceutical composition comprising the polymorphic prasugrel-hydrogen sulfate in a specific amount as an active ingredient together with optional additives such as carriers, diluents, or excipients may be prepared according to conventional methods {see, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 19th Edition, 1995).
The pharmaceutical composition of the present invention may comprise the polymorphic prasugrel-hydrogen sulfate in an amount ranging from 0.1 to 95% by weight, preferably from 1 to 70% by weight based on the total weight thereof.
In the present invention, a proposed daily dose of the polymorphic prasugrel-hydrogen sulfate as an active ingredient for administration to a mammal including human is about from 0.5 to 250 mg/kg body weight, preferably about from 1 to 150 mg/kg body weight, which may be administered in a single dose or in divided doses.
The following examples illustrate the embodiments of the present invention in more detail. However, the following examples of the present invention are merely examples, and the present invention is not limited thereto.
The chemical purities shown in the following Examples were calculated by percentage (%) of the peak area of prasugrel to the total peak area (except for the peak area of solvent) based on the liquid chromatography analysis performed under the following conditions:
Column: Capcell PCK MG CI 8™ (diameter 4.6 mm x length 1 0 mm, particle size: 5 μηι);
Detector and wavelength: UV absorption spectrometer (240 nm);
Mobile phase: 0.02M phosphate buffered solution/acetonitrile = 30/70 (v/v %); and
Flow rate: 1.0 ml/min.
The melting point of the inventive polymorphic prasugrel-hydrogen sulfate was determined using a capillary digital melting point recorder (Barnstead Electrothermal, Great Britain). The water content of the inventive polymorphic prasugrel-hydrogen sulfate was measured using 795 KFT water meter (Metrohm, Switzerland), and the infrared absorption spectrum (IR) was obtained using MB- 100 infrared spectrometer (Bomen, Canada). 1H nuclear magnetic resonance (1H-NMR) spectrum was measured using Avance DPX 300 (Bruker, Germany). Differential scanning calorimeter (DSC) scan was obtained using STA S-1000 (Scinco, Korea) with a temperature programming rate of 10 °C per a minute. The water content was determined by performing dynamic vapor sorption (DVS) twice, are, moisture sorption and the other, adsorption under the conditions of 25 °C and relative humidity of 0 to 90 %, using DVS Advantage 1 dynamic vapor sorption system (Surface Measurement System, Great Britain). X-ray diffraction (XRD) spectra were obtained using CuKa radiation (wavelength λ=1.54056 A) according to a conventional method described in [U.S. Pharmacopeia 31 NF26] using D8 Advance X-ray diffraction analyzer (Bruker, Germany).
Example 1: Preparation of the crystalline form (I) of prasugrel-hydrogen sulfate for seeding
To a suspension of prasugrel (1.0 g, 2.68 mmol) in isopropanol (5 ml), sulfuric acid (0.13 g, 1.33 mmol) was added slowly to convert the suspension into a homogenous phase. The resulting clear solution was stirred at room temperature for 24 hours and kept in a refrigerator for 5 days. The solid formed was filtered, washed with a small amount of isopropanol, and dried at 40 °C , to obtain the title compound as a white colored crystal (0.3 g). Example 2: Preparation of the crystalline form (I) of prasugrel-hydrogen sulfate
To a suspension of prasugrel (2.0 g, 5.35 mmol) in isopropanol (20 ml), sulfuric acid (0.52 g, 5.30 mmol) was added slowly to convert the suspension into a homogenous phase. The prasugrel-hydrogen sulfate obtained in Example 1 was added thereto and stirred at room temperature for 6 hrs. The solid formed was filtered, washed with isopropanol (5 ml), and dried at 40 °C , to obtain the title compound as a white colored crystal (2.0 g, 80 %).
Melting point : 104 °C to 107 °C (melting)
Water content : 0.32 %
Chemical purity : 98.7 %
1H-NMR (CDC13, ppm): δ 7.7(t, 1H), 7.5(m, 1H), 7.4(m, 1H), 7.2(t, 1H), 6.3(s, 1H), 5.6(bs, 1H), 4.0(m, 2H), 3.4-3.2(m, 2H), 3.0(bm, 2H), 2.3(s, 3H), 2.0(m, 1H), 1.2(m, 2H), 1.0(m, 1H), 0.9(m, 1H).
IR (KBr, cm-1): 3403, 1764, 1712, 1614, 1588, 1495, 1452, 1377, 1 193, 1123, 1080, 1045, 883, 769, 649, 591.
XRD spectrum (CuKa radiation) : 2 theta (20) major peaks having relative peak intensity of at least 25.0 % (I/I0; I: the peak intensity; and I0: the peak intensity of the maximum peak) and the distances between crystal facets (d) are shown in Table 1.
<Table 1>
Figure imgf000013_0001
DSC (10 °C/min) : A DSC scan showed endothermic peak with an onset point at 105.18 °C and a minimum point at 115.87 °C which corresponds to the melting point of said compound as shown in Fig. 2.
Example 3: Preparation of the crystalline form (I) of prasugrel-hydrogen sulfate
To a suspension of prasugrel (2.0 g, 5.35 mmol) in 2-butanol (10 ml), sulfuric acid (0.52 g, 5.30 mmol) was added slowly. The resulting solution was stirred at room temperature for 12 hrs and cooled slowly to precipitate a solid. The solid thus formed was filtered, washed with 2-butanol (5 ml), and dried at 40 °C, to obtain the title compound as a white colored crystal (1.9 g, 75 %).
Melting point : 105 °C to 107 °C (melting)
Water content : 0.10 %
Chemical purity : 98.7 %
The results of 1H-NMR, IR, XRD and DSC are identical to those of
Example 2.
Example 4: Preparation of the crystalline form (I) of prasugrel-hydrogen sulfate
To a suspension of prasugrel (2.0 g, 5.35 mmol) in a mixture of isopropanol (10 ml) and ethyl acetate (10 ml), sulfuric acid (0.52 g, 5.30 mmol) was added slowly to convert into a homogenous phase. The resulting clear reaction solution was stirred at room temperature for 12 hrs. The solid formed was filtered, washed with isopropanol (10 ml), and dried at 40 °C, to obtain the title compound as a white colored crystal (2.0 g, 79 %).
Melting point : 104 °C to 106 °C (melting)
Water content : 0.25 %
Chemical purity : 98.5 %
The results of 1H-NMR, IR, XRD and DSC are identical to those of
Example 2. Example 5: Preparation of the crystalline form (I) of prasugrel-hydrogen sulfate
To a suspension of prasugrel (20 g, 53.6 mmol) in isopropanol (200 ml) sulfuric acid (5.24 g, 53.4 mmol) was added slowly and stirred at room temperature for 6 hrs. The solid formed was filtered, washed with isopropanol (30 ml), and dried at 40 °C , to obtain the title compound as a white colored crystal (21.2 g, 84 %).
Melting point : 104 °C to 107 °C (melting)
Water content : 0.32 %
Chemical purity : 98.7 %
The results of 1H-NMR, IR, XRD and DSC are identical to those of Example 2. Example 6: Preparation of the crystalline form (II) of prasugrel-hydrogen sulfate
The crystalline form (I) of prasugrel-hydrogen sulfate obtained in Example 5 (10 g, 21.2 mmol) was added to metylethylketone (25 ml) and heated at 50 °C to dissolve. The resulting reaction solution was cooled and stirred at room temperature for 12 hrs. The solid formed was filtered, washed with isopropyl ether (15 ml), and dried at 40 °C , to obtain the title compound as a white colored crystal (7.6 g, 76 %).
Melting point : 156 °C to 160 °C (melting)
Water content : 0.25 %
Chemical purity : 99.2 %
1H-NMR (CDC13, ppm): δ 7.7(t, 1H), 7.5(m, 1H), 7.4(m, 1H), 7.2(t, 1H), 6.3(s, 1H), 5.6(bs, 1H), 4.0(m, 2H), 3.4-3.2(m, 2H), 3.0(bm, 2H), 2.3(s, 3H), 2.0(m, 1H), 1.2(m, 2H), 1.0(m, 1H), 0.9(m, 1H).
IR (KBr, cm"1): 3405, 1758, 1710, 1588, 1495, 1452, 1374, 1 191, 1 123, 1080, 884, 768, 647, 591, 450.
XRD spectrum (CuKa radiation) : 2 theta (2Θ) major peaks having relative peak intensity of at least 25.0 % (I/I0; I: the peak intensity; and 1Q: the peak intensity of the maximum peak), and the distances between crystal facets (d) are shown in Table 2. Said major peaks are shown in Fig. 3.
<Table 2>
Figure imgf000016_0001
DSC (10 °C/min) : A DSC scan showed endothermic peak with an onset point at 162.46 °C and a minimum point at 167.91 °C which corresponds to the melting point of said compound as shown in Fig. 4.
Water content: As shown in Fig. 5, the compound did not absorb moisture under the room humidity level when the water content was measured with 795 KFT moisture tester (Metrohmco. Ltd., Switzerland).
Example 7: Preparation of the crystalline form (II) of prasugrel-hydrogen sulfate
The crystalline form (I) of prasugrel-hydrogen sulfate obtained in Example 3 (10 g, 21.2 mmol) was added to metylethylketone (3 ml) and heated at 60 °C to dissolve. The resulting reaction solution was stirred at room temperature for 24 hrs. The solid formed was filtered, washed with isopropyl ether (5 ml), and dried at 40 °C , to obtain the title compound as a white colored crystal (0.8 g, 80 %).
Melting point : 156 °C to 159 °C (melting)
Water content : 0.2 %
Chemical purity : 99.1 % The results of 1H-NMR, IR, XRD and DSC are identical to those of Example 6.
Example 8: Preparation of the crystalline form (II) of prasugrel-hydrogen sulfate
The crystalline form (I) of prasugrel-hydrogen sulfate obtained in Example 3 (1.0 g, 2.12 mmol) was added to acetone (3 ml) and heated at 50 °C to dissolve. The resulting reaction solution was stirred at room temperature for 24 hrs. The solid formed was filtered, washed with isopropyl ether (5 ml), and dried at 40 °C, to obtain the title compound as a white colored crystal (0.5 g, 50 %).
Melting point : 155 °C to 158 °C (melting)
Water content : 0.2 %
Chemical purity : 99.2 %
The results of 1H-NMR, IR, XRD and DSC are identical to those of Example 6.
Example 9: Preparation of the crystalline form (II) of prasugrel-hydrogen sulfate
The crystalline form (I) of prasugrel-hydrogen sulfate obtained in Example 3 (1.0 g, 2.12 mmol) was added to a mixture of acetone (3 ml) and ethyl acetate (3 ml) and heated at 50 °C to dissolve. The resulting reaction solution was stirred at room temperature for 12 hrs. The solid formed was filtered, washed with isopropyl ether (5 ml), and dried at 40 "C , to obtain the title compound as a white colored crystal (0.7 g, 70 %).
Melting point : 153 °C to 156 °C (melting)
Water content : 0.2 %
Chemical purity : 99.0 %
The results of 1H-NMR, IR, XRD and DSC are identical to those of Example 6. Example 10: Preparation of the crystalline form (II) of prasugrel-hydrogen sulfate To a suspension of prasugrel (2.0 g, 5.35 mmol) in methyl ethyl ketone (5 ml), sulfuric acid (0.52 g, 5.30 mmol) was added slowly to convert the suspension into a homogenous phase. The crystalline form (II) of prasugrel-hydrogen sulfate obtained in Example 6 was added thereto and stirred at room temperature for 6 hrs. The solid formed was filtered, washed with isopropyl ether (5 ml), and dried at 40 °C , to obtain the title compound as a white colored crystal (2.1 g, 84 %).
Melting point : 156 °C to 159 °C (melting)
Water content : 0.2 %
Chemical purity : 99.1 %
The results of 1H-NMR, IR, XRD and DSC are identical to those of
Example 6.
Experimental Example 1: Solubility evaluation The Solubility of the polymorphic prasugrel-hydrogen sulfate obtained in
Example 5 and 6 (crystallines form (I) and (II)) in pH 1.2(first solution), pH 6.8 (second solution) and distilled water was measured. As a comparative example, prasugrel hydrochloride prepared according to the preparation method described in WO 2002/04461 was used. The results were showed in Table 3.
<Table 3>
Figure imgf000019_0001
As showed in Table 3, the prasugrel-hydrogen sulfate (crystalline forms (I) and (II)) has an improved solubility compared to prasugrel hydrochloride.
The prasugrel-hydrogen sulfate (crystalline forms (I) and (II)) of the present invention is characterized by the melting point, diffraction angle peaks and the distances between crystal facets in XRD spectrum analysis, and the temperature in endothermic peaks exhibited by DSC scan.
The non-hygroscopicity is an important characteristic required for formulating a pharmaceutical composition and preserving a drug. The crystalline form (I) of prasugrel-hydrogen sulfate has a hygroscopicity under the room humidity level, while the crystalline form (II) of prasugrel-hydrogen sulfate has non-hygroscopicity in the same conditions. Accordingly, the crystalline form (II) of prasugrel-hydrogen sulfate according to the present invention meets such requirement. Further, the crystalline form (II) meets physical and chemical requirements required for a pharmaceutical ingredient such as an antistatic feature and excellent particle flowability and water-solubility.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A polymorphic prasugrel-hydrogen sulfate of formula (I) of crystalline form (I) whose X-ray diffraction spectrum obtained using Cu-Κα radiation shows major peaks at diffraction angles (2Θ) of 8.3±0.2°, 12.0±0.2\ 12.4±0.2°, 19.1±0.2\ 19.5±0.2\ 22 6±0.2\ 23.2±0.2\ and 23.8±0.2°:
Figure imgf000020_0001
2. The polymorphic prasugrel-hydrogen sulfate of claim 1, whose melting point is in the range of 104 °C to 107 °C .
3. The polymorphic prasugrel-hydrogen sulfate of claim 2, whose differential scanning calorimetry scan shows an endothermic peak with an onset point at 105.18±2 °C and a minimum peak point at 115.87±2 °C .
4. A polymorphic prasugrel-hydrogen sulfate of formula (II) of crystalline form (II) whose X-ray diffraction spectrum obtained using Cu-Κα radiation shows major peaks at diffraction angles (20) of 8.6±0.2°, 12.8±0.2\ 13.7±0.2\ 17.
5±0.2\ 19.3±0.2\ ±0.2\ 22.6±0.2\ 23.7±0.2°, and 24.2±0.2°:
Figure imgf000020_0002
The polymorphic prasugrel-hydrogen sulfate of claim 4, whose melting is in the range of 153 °C to 160 °C .
6. The polymorphic prasugrel-hydrogen sulfate of claim 5, whose differential scanning calorimetry scan shows an endothermic peak with an onset point at 162.46±2 °C and a minimum peak point at 167.91±2 °C .
7. A method for preparing the polymorphic prasugrel-hydrogen sulfate of crystalline form (I) of claim 1, which comprises the step of treating prasugrel with sulfuric acid in an inert organic solvent to induce crystallization of the prasugrel- hydrogen sulfate, wherein the inert organic solvent is CrC6 alcohol or a mixture of CrC6 alcohol and at least one solvent selected from the group consisting of ester, ether and nitriles.
8. The method of claim 7, wherein the inert organic solvent is selected from the group consisting of isopropanol, 2-butanol, a mixture of isopropanol and ethyl acetate, and a mixture of 2-butanol and ethyl acetate.
9. The method of claim 7, wherein the sulfuric acid is used in an amount corresponding to 0.7 to 1.5 mole equivalents based on 1 mole equivalent of the prasugrel.
10. A method for preparing the polymorphic prasugrel-hydrogen sulfate of crystalline form (II) of claim 4, which comprises the step of treating prasugrel with sulfuric acid in an inert organic solvent to induce crystallization of the prasugrel-hydrogen sulfate, wherein the inert organic solvent is ketone or a mixture of ketone and at least one solvent selected from the group consisting of ester, ether and nitriles.
11. The method of claim 10, wherein the inert organic solvent is selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, diethyl ketone, and a mixture of acetone and ethyl acetate.
12. The method of claim 10, wherein the sulfuric acid is used in an amount corresponding to 0.7 to 1.5 mole equivalents based on 1 mole equivalent of the prasugrel.
13. A pharmaceutical composition for preventing or treating an ischemic disease which comprises the polymorphic prasugrel-hydrogen sulfate of claim 1 or 4 as an active ingredient, together with a pharmaceutically acceptable carrier, diluent, or excipient.
14. The pharmaceutical composition of claim 13, which is formulated for oral administration.
15. The pharmaceutical composition of claim 13, wherein the polymorphic prasugrel-hydrogen sulfate is employed in an amount ranging from 0.1 to 95 % by weight based on the total weight of the pharmaceutical composition.
PCT/KR2010/005632 2009-09-01 2010-08-24 Novel polymorphic form of prasugrel-hydrogen sulfate WO2011027988A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090081911A KR20110024057A (en) 2009-09-01 2009-09-01 Novel polymorphic prasugrel hydrogensulfate
KR10-2009-0081911 2009-09-01

Publications (2)

Publication Number Publication Date
WO2011027988A2 true WO2011027988A2 (en) 2011-03-10
WO2011027988A3 WO2011027988A3 (en) 2011-07-21

Family

ID=43649754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005632 WO2011027988A2 (en) 2009-09-01 2010-08-24 Novel polymorphic form of prasugrel-hydrogen sulfate

Country Status (2)

Country Link
KR (1) KR20110024057A (en)
WO (1) WO2011027988A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102977116A (en) * 2012-12-24 2013-03-20 天津大学 Amorphous prasugrel hydrogen sulfate and preparation method thereof
WO2013150322A1 (en) 2012-04-02 2013-10-10 Egis Pharmaceuticals Public Limited Company Prasugrel-containing immediate release stable oral pharmaceutical compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148023B1 (en) * 1991-09-09 1998-08-17 가와무라 요시부미 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting
WO2007114526A1 (en) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof
CN101177430A (en) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 Hydrogenated pyridine derivative and method for preparing salt thereof
CN101255169A (en) * 2008-03-26 2008-09-03 山东大学 Prasugrel salt and preparation method thereof
WO2009066326A2 (en) * 2007-11-19 2009-05-28 Msn Laboratories Limited Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148023B1 (en) * 1991-09-09 1998-08-17 가와무라 요시부미 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting
WO2007114526A1 (en) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof
WO2009066326A2 (en) * 2007-11-19 2009-05-28 Msn Laboratories Limited Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
CN101177430A (en) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 Hydrogenated pyridine derivative and method for preparing salt thereof
CN101255169A (en) * 2008-03-26 2008-09-03 山东大学 Prasugrel salt and preparation method thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013150322A1 (en) 2012-04-02 2013-10-10 Egis Pharmaceuticals Public Limited Company Prasugrel-containing immediate release stable oral pharmaceutical compositions
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
CN102977116A (en) * 2012-12-24 2013-03-20 天津大学 Amorphous prasugrel hydrogen sulfate and preparation method thereof
CN102977116B (en) * 2012-12-24 2014-12-03 天津大学 Amorphous prasugrel hydrogen sulfate and preparation method thereof

Also Published As

Publication number Publication date
KR20110024057A (en) 2011-03-09
WO2011027988A3 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
EP2112155B1 (en) Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
JP2009514988A (en) Imatinib base and imatinib mesylate and methods for their preparation
US11286259B2 (en) Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
JP2023145680A (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using the same
US20220002297A1 (en) Polymorphs of x842
KR20080090661A (en) Crystalline hydrate of bepotastine metal salt, method for preparing same and pharmaceutical composition comprising same
US8772488B2 (en) Crystals of prasugrel hydrobromate
US20220055995A1 (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
WO2011027988A2 (en) Novel polymorphic form of prasugrel-hydrogen sulfate
WO2009075504A2 (en) Crystalline form of bepotastine p-toluenesulfonate, method for preparing same and pharmaceutical composition containing same
US10377725B2 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
KR101336143B1 (en) Clopidogrel co-crysral
WO2011016686A2 (en) Prasugrel disulfonate or crystalline forms thereof, method for preparing same, and pharmaceutical composition containing same
TWI834634B (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same
KR101423630B1 (en) Co-crystals of Bicalutamide and Nicotinamide
US11820772B2 (en) Polymorphs of the hydrochloride salt of linaprazan glurate
KR101307712B1 (en) Crystalline hydrate of bepotastine metal salt, method for preparing same and pharmaceutical composition comprising same
JP2023504015A (en) Bile acid derivative salts, crystal structures thereof, methods for their preparation and use
KR20160146428A (en) Stable amorphous solifenacin pharmaceutical composition containing solifenacin or its pharmaceutically acceptable salt and lactose, and method of preparation thereof
JP2023533874A (en) PN6047 hydrochloride polymorph
EA045339B1 (en) CRYSTALINE AND SALT FORMS OF ORGANIC COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS
WO2013010502A1 (en) Acid addition salt of prasugrel, preparation method therefor and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10813897

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10813897

Country of ref document: EP

Kind code of ref document: A2